Determination of inflammatory biomarkers in patients with COPD: A comparison of different assays

BMC Medical Research Methodology

Volumn 12, Issue , 2012, Pages

  Lápez Campos, José L ^a,b   Arellano, Elena ^b   Calero, Carmen ^a,b   Delgado, Ana ^a   Márquez, Eduardo ^a   Cejudo, Pilar ^a   Ortega, Francisco ^a,b   Rodríguez Panadero, Francisco ^a,b   Montes Worboys, Ana ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; SERUM AMYLOID A;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PHOTOMETRY; PHYSIOLOGY; SPAIN;

ACUTE-PHASE PROTEINS; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SERUM AMYLOID A PROTEIN; SPAIN;

EID: 84859090158     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-12-40     Document Type: Article

References (37)

1. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Barnes PJ, Shapiro SD, Pauwels RA, Eur Respir J 2003 22 672 688 10.1183/09031936.03.00040703 14582923 (Pubitemid 37258549)
2. Systemic manifestations and comorbidities of COPD. Barnes PJ, Celli BR, Eur Respir J 2009 33 1165 1185 10.1183/09031936.00128008 19407051
3. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B, Thorax 2007 62 595 601 10.1136/thx.2006. 064428 17356059 (Pubitemid 47056886)
4. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Ridker PM, Circulation 2003 107 363 369 10.1161/01.CIR.0000053730.47739.3C 12551853 (Pubitemid 36158034)
5. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG, Am J Respir Crit Care Med 2007 175 250 255 17053205 (Pubitemid 46203128)
6. C-reactive protein in patients with COPD, control smokers and non-smokers. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR, Thorax 2006 61 23 28 16143583 (Pubitemid 43106973)
7. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. de Torres JP, Cordoba-Lanus E, Lápez-Aguilar C, Muros de Fuentes M, Montejo De Garcini A, Aguirre-Jaime A, Celli BR, Casanova C, Eur Respir J 2006 27 902 907 16455829 (Pubitemid 44911101)
8. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Antonescu-Turcu AL, Tomic R, Curr Opin Pulm Med 2009 15 120 125 10.1097/MCP.0b013e3283218603 19532026
9. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Steel DM, Whitehead AS, Immunol Today 1994 15 81 88 10.1016/0167-5699(94)90138-4 8155266 (Pubitemid 24049801)
10. Acute-phase proteins and other systemic responses to inflammation. Gabay C, Kushner I, N Engl J Med 1999 340 448 454 10.1056/NEJM199902113400607 9971870 (Pubitemid 29084777)
11. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, Karlsson AS, Silvestrini R, Smallwood D, Vlahos R, Irving LB, Anderson GP, Am J Respir Crit Care Med 2008 177 269 278 18006888 (Pubitemid 351198369)
12. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Koutsokera A, Kiropoulos TS, Nikoulis DJ, Daniil ZD, Tsolaki V, Tanou K, Papaioannou AI, Germenis A, Gourgoulianis KI, Kostikas K, Respir Med 2009 103 919 926 10.1016/j.rmed.2008.12.006 19121927
13. Reduced soluble receptor for advanced glycation end products in chronic obstructive pulmonary disease. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW, Eur Respir J 2011 37 516 522 10.1183/09031936.00029310 20595148
14. C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Dahl M, Vestbo J, Zacho J, Lange P, Tybjærg-Hansen A, Nordestgaard BG, Thorax 2011 66 197 204 10.1136/thx.2009.131193 21059738
15. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Agustí A, Proc Am Thorac Soc 2007 4 522 525 10.1513/pats.200701-004FM 17878464 (Pubitemid 47547846)
16. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, Olafsson I, Benediktsdottir B, Janson C, Buist AS, Gislason T, Respir Med 2009 103 1548 1553 10.1016/j.rmed.2009.04.005 19427181
17. Validation of a combined comorbidity index. Charlson M, Szatrowski TP, Peterson J, Gold J, J Clin Epidemiol 1994 47 1245 1251 10.1016/0895-4356(94) 90129-5 7722560 (Pubitemid 24361532)
18. Standardisation of spirometry. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS/ERS Task Force, Eur Respir J 2005 26 319 338 10.1183/09031936.05.00034805 16055882 (Pubitemid 41079078)
19. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH, BMJ 1959 5147 257 266
20. Statistical methods for assessing observer variability in clinical measures. Brennan P, Silman A, BMJ 1992 304 1491 1494 10.1136/bmj.304.6840.1491 1611375
21. Statistical methods for assessing agreement between two methods of clinical measurement. Bland JM, Altman DG, Lancet 1986 1 307 310 2868172 (Pubitemid 16134762)
22. A panel of multiple markers associated with chronic systemic inflammation and the risk of atherogenesis is detectable in asthma and chronic obstructive pulmonary disease. Wu TL, Chang PY, Tsao KC, Sun CF, Wu LL, Wu JT, J Clin Lab Anal 2007 21 367 371 10.1002/jcla.20197 18041101 (Pubitemid 350250403)
23. High value of combined serum C-reactive protein and BODE score for mortality prediction in patients with stable COPD. Liu SF, Wang CC, Chin CH, Chen YC, Lin MC, Arch Bronconeumol 2011 47 427 432 21821335
24. Targeting C-reactive protein for the treatment of cardiovascular disease. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP, Nature 2006 440 1217 1221 10.1038/nature04672 16642000
25. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR, N Engl J Med 2002 347 1557 1565 10.1056/NEJMoa021993 12432042 (Pubitemid 35315836)
26. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Pepys MB, Baltz ML, Adv Immunol 1983 34 141 212 6356809 (Pubitemid 14089437)
27. Serum amyloid A protein in amyloidosis, rheumatic, and neoplastic diseases. Benson MD, Cohen AS, Arthritis Rheum 1979 22 36 42 10.1002/art.1780220106 103558 (Pubitemid 9167565)
28. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Malle E, De Beer FC, Eur J Clin Invest 1996 26 427 435 10.1046/j.1365-2362.1996.159291.x 8817153 (Pubitemid 26226404)
29. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. Clifton PM, Mackinnon AM, Barter PJ, J Lipid Res 1985 26 1389 1398 4086942 (Pubitemid 16189736)
30. Influence of serum amyloid A protein on high-density lipoprotein in chronic inflammatory disease. Kumon Y, Suehiro T, Ikeda Y, Yoshida K, Hashimoto K, Ohno F, Clin Biochem 1993 26 505 511 10.1016/0009-9120(93)80016-N 8124866 (Pubitemid 24029795)
31. The use and limitations of laser nephelometry. Bergmann KC, Crisci CD, Oehling A, Allergol Immunopathol (Madr) 1981 9 55 62 (Pubitemid 11158953)
32. Routine quantitation of rheumatoid factors: ELISA or nephelometry? Adebajo AO, Cawston TE, Hazleman BL, Scand J Rheumatol 1992 21 302 304 10.3109/03009749209099246 1475641 (Pubitemid 23015617)
33. Concentrations of plasma immunoglobulins in the dog as determined by laser nephelometry. Comparison with radial immunodiffusion and enzyme-linked immunosorbent assay. Ginel PJ, Margarito JM, Lucena R, Molleda JM, Eur J Clin Chem Clin Biochem 1997 35 223 228 9127744 (Pubitemid 27192981)
34. Discrepancies between qualitative and quantitative analysis of cerebrospinal fluid IgG: densitometric comparison of nephelometry-silver versus immuno-enzymes. Keir G, Barrio S, Thompson EJ, Ann Clin Biochem 2008 45 Pt 4 404 408 18583626 (Pubitemid 352031548)
35. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM, Thorax 2006 61 17 22 16055618 (Pubitemid 43106972)
36. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Sin DD, Lacy P, York E, Man SF, Am J Respir Crit Care Med 2004 170 760 765 10.1164/rccm.200404-543OC 15229100 (Pubitemid 39298991)
37. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie RL, Williams D, Gan WQ, Rousseau R, ABC (Advair Biomarkers in COPD) Investigators, Am J Respir Crit Care Med 2008 177 1207 1214 10.1164/rccm.200709-1356OC 18310480 (Pubitemid 351860929)